TARGETING NEWLY IDENTIFIED ER beta/TGF-beta 1/SMAD3 SIGNALS WITH THE FDA-APPROVED ANTI-ESTROGEN FASLODEX OR AN ER beta SELECTIVE ANTAGONIST IN RENAL CELL CARCINOMA
JOURNAL OF UROLOGY(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF UROLOGY(2019)